Your browser doesn't support javascript.
loading
Perspectives on biomedical HIV prevention options among women who inject drugs in Kenya.
Bazzi, Angela Robertson; Yotebieng, Kelly A; Agot, Kawango; Rota, Grace; Syvertsen, Jennifer L.
Afiliación
  • Bazzi AR; a Department of Community Health Sciences , Boston University School of Public Health , Boston , MA , USA.
  • Yotebieng KA; b Department of Anthropology , The Ohio State University , Columbus , OH , USA.
  • Agot K; c Impact Research & Development Organization , Kisumu , Kenya.
  • Rota G; d Kenya Medical Research Institute , Kisumu , Kenya.
  • Syvertsen JL; e Department of Anthropology , University of California at Riverside , CA , USA.
AIDS Care ; 30(3): 343-346, 2018 03.
Article en En | MEDLINE | ID: mdl-28780885
Due to heightened vulnerability to HIV from frequent engagement in sex work and overlapping drug-using and sexual networks, women who inject drugs should be a high priority population for pre-exposure prophylaxis (PrEP) and other biomedical HIV prevention tools. Kenya is one of the first African countries to approve oral PrEP for HIV prevention among "key populations," including people who inject drugs and sex workers. The objective of this study was to explore preferences and perceived challenges to PrEP adoption among women who inject drugs in Kisumu, Kenya. We conducted qualitative interviews with nine HIV-uninfected women who inject drugs to assess their perceptions of biomedical HIV interventions, including oral PrEP, microbicide gels, and intravaginal rings. Despite their high risk and multiple biomedical studies in the region, only two women had ever heard of any of these methods. All women were interested in trying at least one biomedical prevention method, primarily to protect themselves from partners who were believed to have multiple other sexual partners. Although women shared concerns about side effects and product efficacy, they did not perceive drug use as a significant deterrent to adopting or adhering to biomedical prevention methods. Beginning immediately and continuing throughout Kenya's planned PrEP rollout, efforts are urgently needed to include the perspectives of high risk women who use drugs in biomedical HIV prevention research and programing.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Conducta Sexual / Infecciones por VIH / Abuso de Sustancias por Vía Intravenosa / Conocimientos, Actitudes y Práctica en Salud / Fármacos Anti-VIH / Profilaxis Pre-Exposición Tipo de estudio: Qualitative_research Límite: Adult / Female / Humans País/Región como asunto: Africa Idioma: En Revista: AIDS Care Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Conducta Sexual / Infecciones por VIH / Abuso de Sustancias por Vía Intravenosa / Conocimientos, Actitudes y Práctica en Salud / Fármacos Anti-VIH / Profilaxis Pre-Exposición Tipo de estudio: Qualitative_research Límite: Adult / Female / Humans País/Región como asunto: Africa Idioma: En Revista: AIDS Care Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido